{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Boorgula GD"],"funding":["NIAID NIH HHS","NIAID"],"pagination":["102289"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9892238"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["138"],"pubmed_abstract":["<h4>Background</h4>There is limited high quality evidence to guide the optimal doses of drugs for the treatment of Mycobacterium kansasii pulmonary disease (Mkn-PD).<h4>Methods</h4>We performed (1) minimum inhibitory concentration experiment, (2) isoniazid dose-response study using the hollow fiber system model (HFS-Mkn) to determine PK/PD optimized exposure, and (3) another HFS-Mkn study to determine the efficacy of high dose isoniazid (15 mg/kg/day) with standard dose rifampin (10 mg/kg/day) and ethambutol (15 mg/kg/day). Inhibitory sigmoid maximal effect model and linear regression was used for data analysis.<h4>Results</h4>MIC of the 20 clinical isolates ranged between 0.5 mg/L to 32 mg/L. In the HFS-Mkn, isoniazid monotherapy failed to control the bacterial growth beyond day 7. On day"],"journal":["Tuberculosis (Edinburgh, Scotland)"],"pubmed_title":["Isoniazid pharmacokinetics/pharmacodynamics as monotherapy and in combination regimen in the hollow fiber system model of Mycobacterium kansasii."],"pmcid":["PMC9892238"],"funding_grant_id":["R01 AI137080","R21 AI148096","U01 AI150508"],"pubmed_authors":["Srivastava S","Heysell SK","Shankar P","Singh S","Boorgula GD","Gumbo T"],"additional_accession":[]},"is_claimable":false,"name":"Isoniazid pharmacokinetics/pharmacodynamics as monotherapy and in combination regimen in the hollow fiber system model of Mycobacterium kansasii.","description":"<h4>Background</h4>There is limited high quality evidence to guide the optimal doses of drugs for the treatment of Mycobacterium kansasii pulmonary disease (Mkn-PD).<h4>Methods</h4>We performed (1) minimum inhibitory concentration experiment, (2) isoniazid dose-response study using the hollow fiber system model (HFS-Mkn) to determine PK/PD optimized exposure, and (3) another HFS-Mkn study to determine the efficacy of high dose isoniazid (15 mg/kg/day) with standard dose rifampin (10 mg/kg/day) and ethambutol (15 mg/kg/day). Inhibitory sigmoid maximal effect model and linear regression was used for data analysis.<h4>Results</h4>MIC of the 20 clinical isolates ranged between 0.5 mg/L to 32 mg/L. In the HFS-Mkn, isoniazid monotherapy failed to control the bacterial growth beyond day 7. On day","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-04T03:00:12.361Z","creation":"2025-04-04T03:00:12.361Z"},"accession":"S-EPMC9892238","cross_references":{"pubmed":["36512853"],"doi":["10.1016/j.tube.2022.102289"]}}